Recor Medical Announces AMA CPT Editorial Panel Approval of Two New Category I CPT® Codes for Renal Denervation

The AMA CPT Editorial Panel created two Category I CPT codes, 37X47 and 37X48, for percutaneous transcatheter renal sympathetic denervation, expected to take effect on January 1, 2028. The codes establish a standardized reporting and potential physician-payment pathway for Recor Medical's FDA-approved Paradise ultrasound renal denervation system in treatment-resistant hypertension. The milestone improves the therapy's reimbursement infrastructure, although CPT assignment does not guarantee payer coverage or payment.

Analysis

The investable implication is less near-term procedure revenue than a reduction in adoption friction for renal denervation (RDN) beginning in 2028. Category I coding permits more consistent physician billing, but the economic bottleneck remains CMS valuation, site-of-service payment and commercial-payer coverage; none is assured by this action. For Otsuka Holdings (TSE:4578), the likely 2026-27 impact is increased hospital committee engagement and registry enrollment rather than a material earnings inflection, while procedure-volume visibility should improve only after payer policies are published.

The more important competitive read-through is that standardized procedure definitions can expand the RDN category rather than confer a durable proprietary advantage. Medtronic (MDT), whose Symplicity Spyral competes in RDN, may benefit from lower category-level reimbursement uncertainty even if Recor's ultrasound system initially has a differentiated coding narrative. Conversely, antihypertensive-drug franchises face only a remote structural risk: RDN is invasive, requires referral infrastructure, and will initially target poorly controlled patients rather than displace broad primary-care prescribing.

Consensus may overvalue the coding milestone because the effective date creates a long gap in which reimbursement economics can disappoint. The key 1-3 month catalyst is whether specialty societies and payers translate coding into favorable coverage language; the 6-18 month signal is procedure growth at early-adopter centers and evidence that hospitals can earn adequate contribution margins. A restrictive Medicare local coverage determination, weak physician work-value assignment, or persistent reliance on prior authorization would falsify the adoption thesis.

Key Decisions for Investors

• No standalone directional trade in TSE:4578 on this announcement: treat as a 2028 reimbursement optionality marker, not a 2026-27 earnings catalyst. Reassess after CMS valuation/payment proposals and major commercial-payer coverage decisions.
• Place MDT on a reimbursement-upside watchlist for 2027-28. A favorable payment framework would validate category expansion and can be more meaningful to MDT's cardiovascular-device growth narrative than current consensus assumes; avoid initiating solely on coding until coverage and payment amounts are known.
• For healthcare portfolios, monitor early-adopter RDN procedure volumes, hospital margin commentary, and payer prior-authorization criteria quarterly. Upgrade category exposure only if volumes accelerate ahead of 2028 without price concessions; downgrade if coverage remains case-by-case.
• Potential relative-value trade only after payment terms emerge: long MDT versus short a broad pharma proxy such as XLV only if RDN adoption demonstrates substitution from chronic drug escalation. Current evidence supports no such substitution trade because the addressable treated population is initially narrow.